Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6524570 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
US6461605 | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(7 years ago) | |
US6177074 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
US6524570 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(7 years ago) | |
US6461605 (Pediatric) | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
May, 2017
(7 years ago) | |
US6177074 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(7 years ago) | |
US6472373 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(6 years ago) | |
US6172046 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(6 years ago) | |
US6472373 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(6 years ago) | |
US6172046 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(6 years ago) |
Rebetol is owned by Merck Sharp Dohme.
Rebetol contains Ribavirin.
Rebetol has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Rebetol are:
Rebetol was authorised for market use on 03 June, 1998.
Rebetol is available in capsule;oral dosage forms.
Rebetol can be used as method of treating hepatitis c viral infection by continuous parenteral admin interferon alpha 2-10 million iu weekly, subcutaneously, injection of polymer-interferon alpha conjugate-polymer is peg-interferon is alpha 2b, method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin, method of using ribavirin in combination with interferon alpha-2b(pegylated and nonpegylated) to treat patients with chronic hepatitis c, method of treating pt with chronic hepatitis c having hcv genotype 1 and viral load greater than 2 million copies/ml to eradicate detectable hcv-rna by admin combination of ribavirin and interferon alfa-2b for a least 24 weeks, method of using peg-intron/rebetol combination therapy and intron/rebetol combination therapy, method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c, method of using rebetol capsules in combination with a conjugate comprising polyethylene glycol(peg) and an alpha interferon, including, for example, peg-intron powder for injection.
The generics of Rebetol are possible to be released after 21 March, 2018.
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of tx a pt suspected of having hepatitis c by admin, in combination, a co...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(7 years ago) | |
US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(7 years ago) | |
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(7 years ago) | |
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(7 years ago) | |
US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(6 years ago) | |
US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(6 years ago) | |
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(6 years ago) | |
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(6 years ago) | |
US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(1 year, 1 month ago) | |
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(7 months ago) |
Rebetol is owned by Schering.
Rebetol contains Ribavirin.
Rebetol has a total of 12 drug patents out of which 12 drug patents have expired.
Expired drug patents of Rebetol are:
Rebetol was authorised for market use on 29 July, 2003.
Rebetol is available in solution;oral dosage forms.
Rebetol can be used as method of using ribavirin in combination with intron a (interferon alpha-2 b recombinant) injection to treat patients with chronic hepatitis c, method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c, method of using ribavirin in combination with interferon alpha-2b(pegylated and nonpegylated) to treat patients with chronic hepatitis c.
The generics of Rebetol are possible to be released after 05 October, 2023.
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...
Dosage: SOLUTION;ORAL